

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

200116.403D1

APPLICATION NO.

09/982,315

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Horst Fisher and Beate Illek

FILING DATE

October 17, 2001

GROUP ART UNIT

1623

RECEIVED

FEB 11 2002

TECH CENTER 1600/290

U.S. PATENT DOCUMENTS

*EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
HO	AA 5,639,661	06/17/97	Welsh and Sheppard	435	252.3	
HO	AB 5,972,995	10/26/99	Fischer et al.	514	456	
HO	AC 6,329,422 B1	12/11/01	Fischer et al.	514	456	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION
				YES NO
HO	AD WO 99/18953	04/22/99	WIPO	

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

HO	AE	Abstract of JP 62-053923, Derwent WPI Acc. No. 87-105816, March 9, 1987.
HO	AF	Abstract of JP 05-236910, Derwent WPI Acc. No. 93-330545, September 17, 1993.
HO	AG	Abstract of JP 07-059548, Derwent WPI Acc. No. 95-135875, March 7, 1995.
HO	AH	Abstract of RU 2,008,015, Derwent WPI Acc. No. 94-277493, February 28, 1994.
HO	AI	Anderson et al., "Generation of cAMP-Activated Chloride Currents by Expression of CFTR," <i>Science</i> 251: 679-682, February 8, 1991.
HO	AJ	Brown et al., "Chemical chaperones correct the mutant phenotype of the Δ F508 cystic fibrosis transmembrane conductance regulator protein," <i>Cell Stress & Chaperones</i> 1(2): 117-125, 1996.
HO	AK	Hwang et al., "Genistein potentiates wild-type and Δ F508-CFTR channel activity," <i>American Journal of Physiology</i> 273(3, part 1): C988-C998, 1997.
HO	AL	Illek et al., "cAMP-independent activation of CFTR Cl channels by the tyrosine kinase inhibitor genistein," <i>American Journal of Physiology</i> 268(4 part 1): C886-C893, 1995.
HO	AM	Knowles et al., "In Vivo Nasal Potential Difference: Techniques and Protocols for Assessing Efficacy of Gene Transfer in Cystic Fibrosis," <i>Human Gene Therapy</i> 6: 445-455, April 1995.
HO	AN	Riordan et al., "Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA," <i>Science</i> 245: 1066-1073, September 8, 1989.
HO	AO	Rubenstein et al., "In Vitro Pharmacologic Restoration of CFTR-mediated Chloride Transport with Sodium 4-Phenylbutyrate in Cystic Fibrosis Epithelial Cells," <i>J. Clin. Invest.</i> 100(10): 2457-2465, November 1997.

EXAMINER

DATE CONSIDERED


* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

RECEIVED

FEB 11 2002

Sheet 2

TECH CENTER 1600/2900

FORM PTO-1449
(REV. 7-80)

FEB 07 2002

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

200116.403D1

APPLICATION NO.

09/982,315

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANTS

Horst Fisher and Beate Illek

FILING DATE

October 17, 2001

GROUP ART UNIT

1623

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	BJ					
	BK					
	BL					
	BM					
	BN					

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>Ho</i>	BO	Scott and Cooperstein, "Ascorbic acid stimulates chloride transport in the amphibian cornea," <i>Investigative Ophthalmology</i> 14(10): 763-766, October 1975.
<i>Ho</i>	BP	Sheppard et al., "Mutations in CFTR associated with mild-disease-form Cl ⁻ channels with altered pore properties," <i>Nature</i> 362: 160-164, March 11, 1993.
<i>Ho</i>	BQ	Smith, "Treatment of cystic fibrosis based on understanding CFTR," <i>J. Inher. Metab. Dis.</i> 18: 508-516, 1995.

EXAMINER

Horst Fisher

DATE CONSIDERED

6/24/04

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).